The lead researcher.

He also said Atala’s tries to commercialize the technique should add some skepticism toward the results, which he nonetheless called extremely interesting preliminary data. By Jeff Donn.. This is the first time that a more intricate organ has been mostly replaced with cells grown from the patient’s own cells. This suggests that cells engineering may one day be a alternative to the shortage of donor organs in this country for all those needing transplants, said Dr. Anthony Atala, the lead researcher. He said he believes the ongoing work offers a model for growing other tissues and organs. The bladder transplants, performed on seven patients ages 4 to 19, online Tuesday in The Lancet medical journal were getting reported. The research team at Children’s Hospital in Boston did the first method in 1999 but wished to make sure it would focus on others.Good tolerability of AEZS-108 was also reflected by a low rate of severe possibly drug-related non-hematological adverse events and including single cases each of nausea, diarrhea, fatigue, health and wellness deterioration , creatinine elevation, and blood potassium decrease. No cardiac toxicity was reported. Conclusion AEZS-108 at a dosage of 267 mg/m2 every 3 weeks was energetic and well tolerated in individuals with endometrial cancer. Hematological toxicity was rapidly reversible, and non-hematological toxicities had been usually not severe, leading to few deviations from planned treatment. The objective response rate of 31 percent compares well with those of single agent platinum or taxane treatment; responders included individuals pre-treated with platinum/taxane combination. Furthermore, the rate of steady disease was 44 percent, producing a Clinical Benefit Price of 74 percent.